| Brexucabtagene Autoleucel studied in …STUDIED_INderived15 of 15show fewer |
|---|
| → studied in | NCT06144606Phase 2 · recruiting Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) · 15 trials list this drug (7 active) | — | — | Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553872Phase 2 · recruiting Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL · 15 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041309enrolling by invitation Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies · 15 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04880434Phase 2 · completed Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) · 15 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07673367Phase 2 · recruiting Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma · 15 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253663Phase 2 · active not recruiting Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia · 15 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02625480Phase 1/Phase 2 · completed Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma · 15 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05776134available Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel · 15 trials list this drug (7 active) | — | — | Acute Lymphoblastic Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02601313Phase 2 · completed Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) · 15 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05537766Phase 2 · terminated Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies · 15 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03642626Phase 2 · active not recruiting MT2017-45: CAR-T Cell Therapy for Heme Malignancies · 15 trials list this drug (7 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02614066Phase 1/Phase 2 · completed A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) · 15 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06482684Phase 2 · recruiting CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma · 15 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03624036Phase 1 · terminated Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma · 15 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04162756approved for marketing Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies · 15 trials list this drug (7 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |